SCHEMBL3210424

SCHEMBL3210424

Clc1ccc(COC2CN3CCC2CC3)cc1

nearest known ligand 0.72

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GLA P06280 1/20 0.54
GAA P10253 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
NPC1 O15118 1/20 0.51
RAB9A P51151 1/20 0.51
LSS P48449 1/20 0.50
CHRNA7 P36544 1/20 0.49
TACR1 P25103 1/20 0.46
CHRM2 P08172 5/20 0.45
CHRM4 P08173 5/20 0.45
CHRM5 P08912 5/20 0.45
CHRM1 P11229 5/20 0.45
CHRM3 P20309 5/20 0.45
CARM1 Q86X55 1/20 0.44
PRMT6 Q96LA8 1/20 0.44
TSHR P16473 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42
MAPT P10636 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3210416 1.00 GLA (0.54) GLAGAASMN1; SMN2NPC1RAB9A
SCHEMBL9707102 0.89 LSS (0.67) GLAGAASMN1; SMN2NPC1RAB9A
Hydrochloric Acid SCHEMBL8988381 0.89 GLA (0.48) GLAGAASMN1; SMN2NPC1RAB9A
Hydrochloric Acid SCHEMBL8988274 0.88 GLA (0.53) GLAGAASMN1; SMN2NPC1RAB9A
Hydrochloric Acid SCHEMBL8988468 0.88 LSS (0.66) GLAGAASMN1; SMN2NPC1RAB9A
SCHEMBL3216580 0.84 CYP1A2 (0.54) CHRNA7TACR1CHRM2CHRM4CHRM5
SCHEMBL3219324 0.84 MEN1 (0.51) CHRNA7TACR1CHRM2CHRM4CHRM5
SCHEMBL3216566 0.84 CYP1A2 (0.54) CHRNA7TACR1CHRM2CHRM4CHRM5
SCHEMBL3219330 0.84 MEN1 (0.51) CHRNA7TACR1CHRM2CHRM4CHRM5
SCHEMBL8988424 0.84 CHRNA7 (0.51) CHRNA7CHRM2CHRM4CHRM5CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100056565-A1 Heterocyclic Derivatives as M3 Muscarinic Receptors ARGENTA DISCOVERY LIMITED (GB) 2010-03-04 US disclosed
EP-2121688-A1 HETEROCYCLIC DERIVATIVES AS M3 MUSCARINIC RECEPTORS Argenta Discovery Ltd (GB) 2009-11-25 EP disclosed
WO-2008099186-A1 HETEROCYCLIC DERIVATIVES AS M3 MUSCARINIC RECEPTORS ARGENTA DISCOVERY LIMITED (GB) 2008-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056565-A1 Heterocyclic Derivatives as M3 Muscarinic Receptors CHRM2, CHRM3, CHRM1 GLA 3206/4885GAA 3872/4885SMN1; SMN2 4051/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.